Understanding the complexity of p53 in a new era of tumor suppression dlvr.it/T85Rzy

A new BRAF inhibitor breaks resistance barriers Trends in Cancer doi.org/10.1016/j.trec… 👉next generation BRAF inhibitor PF-07799933 with efficacy against mutations across all classes 👉no effect on WT BRAF/CRAF heterodimers 🧐🎯BRAF is getting more effective ESMO - Eur. Oncology

MSI testing, is vital in diagnosing and treating cancers. This groundbreaking approach led to life-changing immunotherapy for a young patient with metastatic colon cancer, showcasing the power of precision medicine. cristina smolenschi Gustave Roussy frontiersin.org/journals/oncol…

🚀 Lancement du consortium #MOSAIC research à Gustave Roussy 🚀 L'objectif du projet MOSAIC research (Multi Omics & Spatial Atlas In Cancer), dont Gustave Roussy est partenaire avec Owkin, est de construire la plus importante base de données multi-omiques en oncologie en

Prognostic value of total tumor volume in CRC liver metastases @OncologyAdvance doi.org/10.1016/j.ejca… 🔎post-hoc of CAIRO5 👉Tumor total volume, but not RECIST 1.1 is prognostic for survival outcomes 👉5-yr Os 72% for TTV of 3 mL vs 7% for TTV of 300 mL ESMO - Eur. Oncology

Bacteria in metastatic sites: Unveiling hidden players in cancer progression dlvr.it/T9Vrt5

✨ Elles sont médecins, chercheuses, scientifiques à Gustave Roussy ✨ Dr Elsa Bernard est cheffe de groupe de l'équipe oncologie clinique computationnelle à Gustave Roussy. Découvrir son portrait ⤵

New article in press: The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ben Westphalen FabriceAndre Vivek Subbiah, MD

Online Now: The KRAS mutational spectrum and its clinical implications in pancreatic cancer dlvr.it/TCXSrH

Bispecific antibodies: advancing precision oncology Trends in Cancer doi.org/10.1016/j.trec… 👉Bispecific antibodies are on the rise with promising data 👏Excellent in depth review ESMO - Eur. Oncology

The KRAS mutational spectrum and its clinical implications in pancreatic cancer dlvr.it/TD68gz

📢 Gustave Roussy, premier centre de lutte contre le cancer en France et en Europe, conserve son rang dans le top 5 mondial des hôpitaux en cancérologie. Pour la 5ème année consécutive, le magazine Newsweek a classé Gustave Roussy dans le top 5 des meilleurs hôpitaux du monde

The integration of #cancer #biomarkers has revolutionized cancer treatment, allowing remarkable advancements in cancer therapeutics & the prognosis of cancer patients. This review paints the road ahead. sciencedirect.com/science/articl…

The UNLOCK program is designed to better understand the mechanisms of action and resistance to innovative drugs through the integration of clinical, translational and fundamental research. #MAP2024 Gustave Roussy Yohann Loriot Friboulet Luc

📆 Journée mondiale du #cancer du pancréas 📆 À l'occasion de cet évènement, Nicolas Wolikow, co-fondateur et président de Cure51, a fait escale à Gustave Roussy pour remettre un trophée symbolique à Julieta Elena, oncologue à l'Institut. 🎯 Le but de cette escale est de

Comparison of 1st chemotherapy in unresectable locally advanced or metastatic #PDAC The Lancet Oncology doi.org/10.1016/S1470-… 🔎systematic review & Bayesian network meta-analysis, 79 trials, 22 168 pts 👉NALIRIFOX & FOLFIRINOX may be the preferred options if feasible ESMO - Eur. Oncology

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma Journal of Hepatology doi.org/10.1016/j.jhep… 🔥Get the new guideline for HCC 👉Up to date, very granular recommendations EASL Education ESMO - Eur. Oncology ILCA #livertwitter

L’espoir de guérir le #cancer a un nom : Gustave Roussy 🤍

Le Président de la République française pose la 1ʳᵉ pierre du futur bâtiment de recherche de Gustave Roussy. 🇫🇷🔬 À l'occasion de la Journée mondiale contre le cancer, Gustave Roussy a eu l'honneur et le plaisir d'accueillir Monsieur Emmanuel Macron et Madame Brigitte Macron,

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial Journal of Clinical Oncology doi.org/10.1200/JCO.24… 👉Supports GemCap for R0 & lymph node-negative patients not eligible for mFOLFIRINOX ESMO - Eur. Oncology EASL Education ILCA Cholangiocarcinoma Foundation